Katarina Stingl

Prof. Katarina Stingl

Center for Ophthalmology, University of Tuebingen, Germany
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Clinical Neurophysiology
Verified
Journal Article
Closed access
LALauren N. Ayton
Lauren N. Ayton
NBNick Barnes
Nick Barnes
GDGislin Dagnelie
Gislin Dagnelie
TFTakashi Fujikado
Takashi Fujikado
GGGeorges Goetz
Georges Goetz
MPMatthew A. Petoe
Matthew A. Petoe

23 August 2017 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
KSKatarina Stingl
Katarina Stingl
RSRuth Schippert
Ruth Schippert
KBKarl U. Bartz-Schmidt
Karl U. Bartz-Schmidt
DBDorothea Besch
Dorothea Besch
CCCharles L. Cottriall
Charles L. Cottriall
EZEberhart Zrenner
Eberhart Zrenner
Purpose: We assessed the safety and efficacy of a technically advanced subretinal electronic implant, RETINA IMPLANT Alpha AMS, in end stage retinal degeneration in an interim analysis of two ongoing prospective clinical trials. The purpose of this article is to describe the interim functional results (efficacy). Methods: The subretinal visual prosthesis RETINA IMPLANT Alpha AMS (Retina Implant AG, Reutlingen, Germany) was implanted in 15 blind patients with hereditary retinal degenerations at four study sites with a follow-up period of 12 months (www.clinicaltrials.gov NCT01024803 and NCT02720640). Functional outcome measures included (1) screen-based standardized 2- or 4-alternative forced-choice (AFC) tests of light perception, light localization, grating detection (basic grating acuity (BaGA) test), and Landolt C-rings; (2) gray level discrimination; (3) performance during activities of daily living (ADL-table tasks). Results: Implant-mediated light perception was observed in 13/15 patients. During the observation period implant mediated localization of visual targets was possible in 13/15 patients. Correct grating detection was achieved for spatial frequencies of 0.1 cpd (cycles per degree) in 4/15; 0.33 cpd in 3/15; 0.66 cpd in 2/15; 1.0 cpd in 2/15 and 3.3 cpd in 1/15 patients. In two patients visual acuity (VA) assessed with Landolt C- rings was 20/546 and 20/1111. Of 6 possible gray levels on average 4.6 ± 0.8 (mean ± SD, n = 10) were discerned. Improvements (power ON vs. OFF) of ADL table tasks were measured in 13/15 patients. Overall, results were stable during the observation period. Serious adverse events (SAEs) were reported in 4 patients: 2 movements of the implant, readjusted in a second surgery; 4 conjunctival erosion/dehiscence, successfully treated; 1 pain event around the coil, successfully treated; 1 partial reduction of silicone oil tamponade leading to distorted vision (silicon oil successfully refilled). The majority of adverse events (AEs) were transient and mostly of mild to moderate intensity. Conclusions: Psychophysical and subjective data show that RETINA IMPLANT Alpha AMS is reliable, well tolerated and can restore limited visual functions in blind patients with degenerations of the outer retina. Compared with the previous implant Alpha IMS, longevity of the new implant Alpha AMS has been considerably improved. Alpha AMS has meanwhile been certified as a commercially available medical device, reimbursed in Germany by the public health system.

21 September 2023 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
NWNicole Weisschuh
Nicole Weisschuh
PMPascale Mazzola
Pascale Mazzola
TZTheresia Zuleger
Theresia Zuleger
KSKarin Schaeferhoff
Karin Schaeferhoff
LKLaura Kühlewein
Laura Kühlewein
THTobias Haack
Tobias Haack
Purpose Genome sequencing (GS) is expected to reduce the diagnostic gap in rare disease genetics. We aimed to evaluate a scalable framework for genome-based analyses ‘beyond the exome’ in regular care of patients with inherited retinal degeneration (IRD) or inherited optic neuropathy (ION). Methods PCR-free short-read GS was performed on 1000 consecutive probands with IRD/ION in routine diagnostics. Complementary whole-blood RNA-sequencing (RNA-seq) was done in a subset of 74 patients. An open-source bioinformatics analysis pipeline was optimised for structural variant (SV) calling and combined RNA/DNA variation interpretation. Results A definite genetic diagnosis was established in 57.4% of cases. For another 16.7%, variants of uncertain significance were identified in known IRD/ION genes, while the underlying genetic cause remained unresolved in 25.9%. SVs or alterations in non-coding genomic regions made up for 12.7% of the observed variants. The RNA-seq studies supported the classification of two unclear variants. Conclusion GS is feasible in clinical practice and reliably identifies causal variants in a substantial proportion of individuals. GS extends the diagnostic yield to rare non-coding variants and enables precise determination of SVs. The added diagnostic value of RNA-seq is limited by low expression levels of the major IRD disease genes in blood.

24 May 2022 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
FRFelix F Reichel
Felix F Reichel
ISImmanuel Seitz
Immanuel Seitz
FWFabian Wozar
Fabian Wozar
SDSpyridon Dimopoulos
Spyridon Dimopoulos
RJRonja Jung
Ronja Jung
MFM. Dominik Fischer
M. Dominik Fischer
Background/aims: Voretigene neparvovec (VN) is the first and only subretinal gene therapy approved by the Food and Drug Administration and European Medicines Agency. Real-world application has started in 2018 in patients with vision impairment due to biallelic retinal pigment epithelium (RPE)65mutation-associated inherited retinal degenerations. Herein, we evaluated the development of retinal atrophy within in a single-centre patient cohort treated with VN.Methods: 13 eyes of eight patients treated with VN were retrospectively analysed for areas of retinal atrophy over a period of 6–24 months following surgery. Ultrawide field images were used to measure the area of atrophy. Fundus autofluorescence imaging is presented as an instrument for early detection of signs of retinal atrophy in these patients.Results: Atrophic changes beyond the retinotomy site were observed in all eyes. Areas of atrophy developed within the area of detachment (bleb) in all eight patients and outside the bleb in three patients. Changes in autofluorescence preceded the development of retinal atrophy and were already evident 2 weeks after surgery in the majority of patients. The areas of atrophy increase with time and progression continued over year 1. Functional outcomes remained stable (VA, FST, visual field).Conclusion: Subretinal injection of VN can lead to RPE atrophy with consequent photoreceptor loss in and outside of the bleb area. Fundus autofluorescence is an important tool to monitor atrophic changes in patients after gene therapy. Interestingly, while areas of atrophy also included central areas, the functional benefits of the treatment did not appear to be affected and remained stable.

21 February 2023 in Ophthalmology
Verified
Journal Article
Closed access
KSKatarina Stingl
Katarina Stingl
KSKrunoslav T. Stingl
Krunoslav T. Stingl
HSHillary Schwartz
Hillary Schwartz
MRMark W. Reid
Mark W. Reid
MKMelanie Kempf
Melanie Kempf
ANAaron Nagiel
Aaron Nagiel

16 September 2014 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
VKVeronique B. D. Kitiratschky
Veronique B. D. Kitiratschky
KSKatarina Stingl
Katarina Stingl
BWBarbara Wilhelm
Barbara Wilhelm
TPTobias Peters
Tobias Peters
DBDorothea Besch
Dorothea Besch
EZEberhart Zrenner
Eberhart Zrenner